UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 17 von 54
Datensatz exportieren als...
BibTeX
Improving the treatment of non‐Hodgkin lymphoma with antibody‐targeted radionuclides
Cancer, 2010-02, Vol.116 (S4), p.1134-1145
Sharkey, Robert M.
Karacay, Habibe
Goldenberg, David M.
2010
Details
Autor(en) / Beteiligte
Sharkey, Robert M.
Karacay, Habibe
Goldenberg, David M.
Titel
Improving the treatment of non‐Hodgkin lymphoma with antibody‐targeted radionuclides
Ist Teil von
Cancer, 2010-02, Vol.116 (S4), p.1134-1145
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2010
Link zum Volltext
Quelle
Alma/SFX Local Collection
Beschreibungen/Notizen
Radioimmunotherapy of non‐Hodgkin lymphoma comprises a 90Y‐ or 131I‐labeled murine anti‐CD20 IgG, but both agents also include a substantial dose of unlabeled anti‐CD20 IgG given immediately before the radioconjugate to reduce its uptake in the spleen (primary normal B‐cell antigen sink); this extends its plasma half‐life and improves tumor visualization. Thus, these treatments combine an effective anti‐CD20 radioconjugate with an unconjugated anti‐CD20 antibody that is also therapeutically active, but the large anti‐CD20 IgG predose (∼900 mg) may diminish the tumor localization of the radioimmunoconjugate (eg, 10‐35 mg). We have examined alternative approaches that enhance radionuclide targeting and improve antitumor responses. One uses a 90Y‐labeled anti‐CD22 IgG (epratuzumab) combined with an antibody therapy regimen of a humanized anti‐CD20 IgG (veltuzumab). Pretargeted radionuclide therapy using a trivalent, humanized, recombinant bispecific anti‐CD20 antibody with a 90Y‐hapten‐peptide is another highly effective method that is also less toxic than directly radiolabeled IgG. Finally, all approaches benefit from the addition of a consolidation‐dosing regimen of the anti‐CD20 IgG antibody. This article reviews these various options and discusses how some fundamental changes could potentially enhance the response and duration from radionuclide‐targeted therapy Cancer 2010;116(4 suppl):1134–45. © 2010 American Cancer Society. Radioimmunotherapy is a safe and effective treatment of non‐Hodgkin lymphoma that combines an anti‐CD20 IgG radioconjugate with a large amount of unlabeled anti‐CD20 antibody intended to allow the radioimmunoconjugate to bypass the CD20 antigen sink, but in excess, it could compromise the efficacy of the radioconjugate. Other approaches, such as combining anti‐CD20 antibody therapy with radioimmunoconjugate that binds to another B‐cell specific antigen, can enhance responses, or in the case of pretargeting procedures with consolidation anti‐CD20 antibody therapy, enhance responses with reduced toxicity.
Sprache
Englisch
Identifikatoren
ISSN: 0008-543X
eISSN: 1097-0142
DOI: 10.1002/cncr.24802
Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2820147
Format
–
Schlagworte
Animals
,
Antibodies, Monoclonal - administration & dosage
,
Antibodies, Monoclonal, Humanized
,
Antigens, CD20 - immunology
,
Biological and medical sciences
,
CD20
,
CD22
,
Hematologic and hematopoietic diseases
,
Humans
,
Immunoconjugates - therapeutic use
,
Indium Radioisotopes
,
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
,
Lymphoma, Non-Hodgkin - radiotherapy
,
Medical sciences
,
Mice
,
Mice, Nude
,
non‐Hodgkin lymphoma
,
pretargeting
,
radioimmunotherapy
,
Radioimmunotherapy - methods
,
Tumors
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX